Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation

Fig. 4

Pioglitazone partially rescues motor behavior in Cox10/DAT-cre mice after 4 months of treatment. a Schematic representation of pioglitazone treatment and experimental time points. b Body weight measurement of 2, 3, 4 and 6-month-old animals: after two months of pioglitazone treatment (4-month-old animals) (dashed line) Cox10/DAT-cre mice showed a significant increase in weight compared to Cox10/DAT-cre mice fed with standard diet (green continuous line) (n = 4). ***p < 0.001: DAT-cre compared to Cox10/DAT-cre; #p < 0.05: Cox10/DAT-cre untreated and treated with Pioglitazone. c Pole test: Cox10/DAT-cre mice displayed decreased latencies times when required to descend a pole, after pioglitazone treatment (n = 4). d, e, f Open field test: Cox10/DAT-cre mice show an increased voluntary movement d, e and an increased rearing activity f after pioglitazone treatment (n = 4)

Back to article page